O
VIVO

OppenheimerFunds’s Meridian Bioscience Inc VIVO Stock Holding History

OppenheimerFunds’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,278
Closed -$144K – 1853
2017
Q4 		$144K Buy
10,278
+266
+3% +$3.89K ﹤0.01% 1824
2017
Q3 		$144K Sell
10,012
-462
-4% -$6.6K ﹤0.01% 1836
2017
Q2 		$165K Sell
10,474
-1,172
-10% -$16.9K ﹤0.01% 1833
2017
Q1 		$161K Buy
+11,646
New +$163K ﹤0.01% 1837

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OppenheimerFunds's VIVO Position: Q1 2018 in Review

OppenheimerFunds sold out of Meridian Bioscience Inc (VIVO) in Q1 2018, closing a stake of 10,278 shares — an estimated $144K sold.

OppenheimerFunds first reported a position in VIVO in Q1 2017 and held it in 4 quarters. The position peaked at $165K in Q2 2017. 186 funds tracked by Wall St. Rank hold VIVO as of Q1 2018.

  • OppenheimerFunds reported no remaining Meridian Bioscience Inc position as of Q1 2018 after selling out during the quarter.
  • OppenheimerFunds sold 10,278 Meridian Bioscience Inc shares in Q1 2018, an estimated $144K.
  • OppenheimerFunds first reported a position in Meridian Bioscience Inc in Q1 2017 and held it in 4 quarters.
  • OppenheimerFunds's Meridian Bioscience Inc position peaked at $165K in Q2 2017.
  • 186 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2018.

Based on OppenheimerFunds's 13F filing for Q1 2018, filed 11 May 2018.